...July 17, 2023 We expect Boston Scientific Corp.'s operating performance will remain in line with our forecast. We also anticipate the company's revenues, earnings, and cash flows will largely remain in line with our expectations. The company continues to benefit from strong organic growth in its newer products, such as WATCHMAN (grew 29% in first-quarter 2023), and we believe EBITDA margins will gradually improve during the year. For full-year 2023, we continue to expect total revenue to increase roughly 9%-10%, driven by strong organic growth and supplemented by moderately sized tuck-in acquisitions. Procedure volume trends are steadily improving, and we believe that a better health care staffing situation will support current positive trends, leading to more product demand. We also project Boston Scientific's S&P Global Ratings-adjusted EBITDA margins will improve 20 basis points to 27.5% based on favorable product mix and improvements in manufacturing efficiency and supply costs. Boston...
